LifeMD just struck a deal that hands it a waiting room of more than 100 million people, and the company's entire bet rests on one thing it cannot control: whether those people actually show up.

The telehealth company announced an exclusive partnership with AT&T on September 15. Starting now, roughly 29 million AT&T wireless and fiber customers across 11 states can enroll in LifeMD's virtual-health membership at no monthly cost. The usual $19-a-month fee is waived entirely. A nationwide expansion planned for January 2027 would extend that offer to more than 100 million eligible customers.

The catch, and it is a meaningful one, is that free membership is not free healthcare. Enrollees still pay for every visit: $29 for message-based consultations, $49 for urgent or primary care video visits, and $79 for specialty care. Insurance, Medicare, and discounted cash-pay rates are accepted. LifeMD makes money only when enrolled customers choose a paid service.

The distribution logic

For a telehealth company, patient acquisition is expensive. You normally buy it through digital advertising, referral networks, or brand recognition built over years. This deal short-circuits some of that. AT&T already has a billing relationship, a mobile app, and a customer-benefits program. LifeMD gets to show up inside that relationship rather than competing for attention on a crowded internet.

Removing the membership fee also lowers the barrier to trying the service. A customer who would have hesitated at $19 a month just to gain access might feel differently when the access itself is free. The question is whether they then feel moved to spend $49 on a video visit they might otherwise handle with an urgent-care Google search.

If they do, the economics can compound. Primary care and chronic-condition management are not one-time transactions. A patient who gets a prescription renewed every month, or who manages a chronic condition through regular check-ins, generates revenue that accumulates over years. LifeMD's bull case is that a large enough fraction of those 100 million-plus eligible customers behave exactly that way.

Where the math gets harder

The partnership's financial structure adds a layer of uncertainty that matters a great deal. According to a regulatory filing LifeMD submitted on September 15, the company will pay AT&T a fixed fee for each lead. The filing does not disclose what that fee is, and it does not set minimum patient or revenue commitments. Future compensation terms are described as subject to negotiation.

That matters because the cost of acquiring a lead is only meaningful relative to what that lead is worth. If LifeMD pays for a large volume of enrollments and only a small fraction ever buy a visit, the cost per paying patient could be steep. Large enrollment numbers, on their own, would say almost nothing about whether this deal is working.

The phased rollout gives LifeMD a chance to measure those conversion rates before committing to a national expansion. If the 11-state pilot shows strong paid utilization, January's broader launch rests on real evidence. If it shows mostly passive enrollments with thin visit volumes, expanding to 100 million-plus customers mostly scales the problem.

Telehealth broadly has been through this cycle before. The pandemic expanded the addressable market dramatically, then showed that access and utilization are not the same thing. Millions of Americans now have telehealth benefits they never use. LifeMD is betting that a zero-dollar entry point, combined with AT&T's trusted relationship with its customers, closes that gap.

The 11-state results, whenever LifeMD reports them, will be the only real answer.